Login / Signup

A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial).

Juwhan ChoiJeong Eun LeeChang-Min ChoiIn Jae OhKye Young LeeTae Won JangSeung-Hyeun LeeEun Young KimDong Won ParkSun Hyo ParkSung-Yong Lee
Published in: Thoracic cancer (2022)
Our study may extend the indications for third-generation EGFR-TKIs to treat patients with stage III NSCLC. Moreover, using this drug to treat stage III NSCLC would emphasize the value of mutation analysis and personalized medicine.
Keyphrases